Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial.
Journal: Alcohol and alcoholism (Oxford, Oxfordshire)
Published: August 19, 2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement.
Journal: Nature reviews. Gastroenterology & hepatology
Published: April 22, 2024
Interaction of Ethanol and Oral ANS-6637, a Selective ALDH2 Inhibitor in Males: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Cohort Study.
Journal: Alcoholism, clinical and experimental research
Published: November 12, 2019
Ranolazine: A potential treatment for refractory neuropathic pain.
Journal: Journal of the neurological sciences
Published: May 24, 2016
In Memory of Adrienne Gordon (1940-2015).
Journal: Alcoholism, clinical and experimental research
Published: June 03, 2015
From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction.
Journal: CNS & neurological disorders drug targets
Published: April 18, 2015
Ranolazine attenuates mechanical allodynia associated with demyelination injury.
Journal: Pain medicine (Malden, Mass.)
Published: August 19, 2014
GS 455534 selectively suppresses binge eating of palatable food and attenuates dopamine release in the accumbens of sugar-bingeing rats.
Journal: Behavioural pharmacology
Published: March 08, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026